JP7150721B2 - Ｃｆｔｒ増強物質としての二環式ヘテロアリール誘導体 - Google Patents

Ｃｆｔｒ増強物質としての二環式ヘテロアリール誘導体 Download PDF

Info

Publication number
JP7150721B2
JP7150721B2 JP2019531417A JP2019531417A JP7150721B2 JP 7150721 B2 JP7150721 B2 JP 7150721B2 JP 2019531417 A JP2019531417 A JP 2019531417A JP 2019531417 A JP2019531417 A JP 2019531417A JP 7150721 B2 JP7150721 B2 JP 7150721B2
Authority
JP
Japan
Prior art keywords
pyrrolo
trifluoromethyl
fluorophenyl
pyrimidin
triazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502103A5 (2
JP2020502103A (ja
Inventor
ジョセフ， ウォルター ストローバッハ，
デイビッド， クリストファー リンブルグ，
ジョン， ポール マティアス，
アトリ トーラレンセン，
ジェイムズ， ジョン ムーソー，
ラジア， アルドリン デニー，
クリストフ， ウルフギャング ツァップ，
イヴァン， ヴィクトロヴィッチ エフレモフ，
Original Assignee
システィック・ファイブロシス・ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by システィック・ファイブロシス・ファンデーション filed Critical システィック・ファイブロシス・ファンデーション
Publication of JP2020502103A publication Critical patent/JP2020502103A/ja
Publication of JP2020502103A5 publication Critical patent/JP2020502103A5/ja
Application granted granted Critical
Publication of JP7150721B2 publication Critical patent/JP7150721B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019531417A 2016-12-16 2017-12-14 Ｃｆｔｒ増強物質としての二環式ヘテロアリール誘導体 Active JP7150721B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662435253P 2016-12-16 2016-12-16
US62/435,253 2016-12-16
PCT/US2017/066317 WO2018112149A1 (en) 2016-12-16 2017-12-14 Bycyclic heteroaryl derivatives as cftr potentiators

Publications (3)

Publication Number Publication Date
JP2020502103A JP2020502103A (ja) 2020-01-23
JP2020502103A5 JP2020502103A5 (2) 2022-05-24
JP7150721B2 true JP7150721B2 (ja) 2022-10-11

Family

ID=62557188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531417A Active JP7150721B2 (ja) 2016-12-16 2017-12-14 Ｃｆｔｒ増強物質としての二環式ヘテロアリール誘導体

Country Status (10)

Country Link
US (4) US10131670B2 (2)
EP (1) EP3554506B1 (2)
JP (1) JP7150721B2 (2)
CN (1) CN110300589B (2)
AU (2) AU2017378324B2 (2)
CA (1) CA3046968A1 (2)
MX (1) MX391651B (2)
RU (1) RU2753056C2 (2)
SG (2) SG10201911076QA (2)
WO (1) WO2018112149A1 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
BR112018009212B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Método para controlar patógenos fúngicos agrícolas
PL3380479T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
AU2016361412A1 (en) 2015-11-25 2018-05-24 Gilead Apollo, Llc Pyrazole ACC inhibitors and uses thereof
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
SI3519401T1 (sl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
AU2017362350B2 (en) 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators
CN110267948B (zh) 2016-12-09 2023-12-08 弗特克斯药品有限公司 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
AU2019222758B2 (en) 2018-02-15 2022-07-07 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TWI848092B (zh) * 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
AU2020290094B2 (en) * 2019-06-10 2024-01-18 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
BR112022000507A2 (pt) 2019-07-15 2022-05-10 Novartis Ag Formulações de (s)-3-amino-6-metóxi-n-(3,3,3-trifluoro-2-hidróxi-2-metilpropil)-5-(trifluorometil)picolinamida
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CA3150162A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
KR20230007369A (ko) * 2020-04-07 2023-01-12 아이테오스 벨지움 에스에이 암의 치료를 위한 ent 저해제로서의 거대환식 다이아민 유도체 및 이와 아데노신 수용체 길항제와의 조합물
IL300413A (en) 2020-08-13 2023-04-01 Vertex Pharma Crystal forms of CFTR modulators
KR20230052954A (ko) 2020-08-20 2023-04-20 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법
EP4225762A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2021397294A1 (en) 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN112876524B (zh) * 2021-01-26 2022-10-28 上海法默生物科技有限公司 一种瑞德西韦中间体的制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
JP2005504751A (ja) 2001-07-23 2005-02-17 バイエル・ヘルスケア・アクチェンゲゼルシャフト ２−アルコキシフェニル置換イミダゾトリアジノン類の使用
US20050085472A1 (en) 2003-06-20 2005-04-21 Masahiro Tanaka Pyrazolo pyrimidine derivatives and methods of use thereof
JP2005538989A (ja) 2002-07-19 2005-12-22 ブリストル−マイヤーズ　スクイブ　カンパニー キナーゼの新規インヒビター
JP2009518303A (ja) 2005-12-02 2009-05-07 バイエル・ヘルスケア・エルエルシー 過剰増殖性疾患および血管新生と関連する疾患を処置するために有用な置換された４−アミノ−ピロロトリアジン誘導体
JP2009522284A (ja) 2005-12-29 2009-06-11 アボット・ラボラトリーズ タンパク質キナーゼ阻害薬
JP2009532507A (ja) 2006-04-04 2009-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｐｉ３キナーゼアンタゴニスト
JP2015500307A (ja) 2011-12-15 2015-01-05 バイエル・ファルマ・アクチェンゲゼルシャフトＢａｙｅｒ Ｐｈａｒｍａ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二置換ベンゾチエニル−ピロロトリアジンおよびｆｇｆｒ阻害剤としてのその使用
JP2016523892A (ja) 2013-07-02 2016-08-12 ライゼン・ファーマシューティカルズ・エスアー Ｐｉ３ｋタンパク質キナーゼ阻害剤、特に、デルタ及び／またはガンマ阻害剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705303A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
CN102770133A (zh) 2010-02-05 2012-11-07 拜耳知识产权有限责任公司 用于治疗囊性纤维化的单独和与PDE5抑制剂组合的sGC刺激剂或sGC激活剂
AU2017362350B2 (en) * 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504751A (ja) 2001-07-23 2005-02-17 バイエル・ヘルスケア・アクチェンゲゼルシャフト ２−アルコキシフェニル置換イミダゾトリアジノン類の使用
JP2005538989A (ja) 2002-07-19 2005-12-22 ブリストル−マイヤーズ　スクイブ　カンパニー キナーゼの新規インヒビター
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
US20050085472A1 (en) 2003-06-20 2005-04-21 Masahiro Tanaka Pyrazolo pyrimidine derivatives and methods of use thereof
JP2009518303A (ja) 2005-12-02 2009-05-07 バイエル・ヘルスケア・エルエルシー 過剰増殖性疾患および血管新生と関連する疾患を処置するために有用な置換された４−アミノ−ピロロトリアジン誘導体
JP2009522284A (ja) 2005-12-29 2009-06-11 アボット・ラボラトリーズ タンパク質キナーゼ阻害薬
JP2009532507A (ja) 2006-04-04 2009-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｐｉ３キナーゼアンタゴニスト
JP2009532476A (ja) 2006-04-04 2009-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア キナーゼ拮抗剤
JP2015500307A (ja) 2011-12-15 2015-01-05 バイエル・ファルマ・アクチェンゲゼルシャフトＢａｙｅｒ Ｐｈａｒｍａ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二置換ベンゾチエニル−ピロロトリアジンおよびｆｇｆｒ阻害剤としてのその使用
JP2016523892A (ja) 2013-07-02 2016-08-12 ライゼン・ファーマシューティカルズ・エスアー Ｐｉ３ｋタンパク質キナーゼ阻害剤、特に、デルタ及び／またはガンマ阻害剤

Also Published As

Publication number Publication date
BR112019012335A2 (pt) 2020-03-03
RU2019120990A3 (2) 2021-01-18
CA3046968A1 (en) 2018-06-21
RU2019120990A (ru) 2021-01-18
US10766904B2 (en) 2020-09-08
SG10201911221RA (en) 2020-02-27
EP3554506A1 (en) 2019-10-23
AU2021277702A1 (en) 2021-12-23
US20190016728A1 (en) 2019-01-17
MX391651B (es) 2025-03-21
US10131670B2 (en) 2018-11-20
SG10201911076QA (en) 2020-01-30
RU2753056C2 (ru) 2021-08-11
US20180170938A1 (en) 2018-06-21
JP2020502103A (ja) 2020-01-23
AU2017378324B2 (en) 2021-09-02
AU2021277702B2 (en) 2023-11-30
AU2017378324A1 (en) 2019-06-27
EP3554506A4 (en) 2020-06-10
US10377762B2 (en) 2019-08-13
WO2018112149A1 (en) 2018-06-21
EP3554506B1 (en) 2021-04-28
US20190016727A1 (en) 2019-01-17
US10208053B2 (en) 2019-02-19
MX2019007135A (es) 2019-11-18
CN110300589B (zh) 2023-03-10
US20190330219A1 (en) 2019-10-31
CN110300589A (zh) 2019-10-01

Similar Documents

Publication Publication Date Title
JP7150721B2 (ja) Ｃｆｔｒ増強物質としての二環式ヘテロアリール誘導体
US12612409B2 (en) Pyrrolopyrimidines as CFTR potentiators
HK40015891A (en) Bycyclic heteroaryl derivatives as cftr potentiators
HK40015891B (en) Bycyclic heteroaryl derivatives as cftr potentiators
BR122024011694A2 (pt) Compostos derivados de heteroarila bicíclica como potenciadores de cftr, composição farmacêutica que compreende os mesmos e uso dos ditos compostos para tratar fibrose cística, asma, bronquiectasia, doença pulmonar obstrutiva crônica, constipação, diabetes mellitus, doença do olho seco, pancreatite, rinossinusite ou síndrome de sjogren
BR122024011694B1 (pt) Compostos derivados de heteroarila bicíclica como potenciadores de cftr, composição farmacêutica que compreende os mesmos e uso dos ditos compostos para tratar fibrose cística, asma, bronquiectasia, doença pulmonar obstrutiva crônica, constipação, diabetes mellitus, doença do olho seco, pancreatite, rinossinusite ou síndrome de sjogren
BR112019012335B1 (pt) Compostos derivados de heteroarila bicíclica como potenciadores de cftr, composição farmacêutica que compreende os mesmos e uso dos ditos compostos para tratar fibrose cística, asma, bronquiectasia, doença pulmonar obstrutiva crônica, constipação, diabetes mellitus, doença do olho seco, pancreatite, rinossinusite ou síndrome de sjogren
HK40014108A (en) Pyrrolopyrimidines as cftr potentiators
HK40014108B (en) Pyrrolopyrimidines as cftr potentiators
BR122022008825B1 (pt) Compostos pirrolopirimidinas potenciadores de cftr, composição farmacêutica que compreende os mesmos e usos terapêuticos dos ditos compostos e composição
BR112019010167B1 (pt) Compostos pirrolopirimidinas potenciadores de cftr

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190912

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220405

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220928

R150 Certificate of patent or registration of utility model

Ref document number: 7150721

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250